Israel Englander Catalyst Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q2 2025

A detailed history of Israel Englander (Millennium Management LLC) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 430,130 shares of CPRX stock, worth $8.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

430,130

Previous 303,533 41.71%

Holding current value

$8.75 Million

Previous $7.36 Million 26.81%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$21.4 - $26.31 $2.71 Million - $3.33 Million	126,597 Added 41.71%	430,130 $9.33 Million
Q1 2025 May 15, 2025	SELL	$19.53 - $25.74 $4.24 Million - $5.59 Million	-217,245 Reduced 41.72%	303,533 $7.36 Million
Q4 2024 Feb 14, 2025	SELL	$19.73 - $23.93 $769,252 - $933,006	-38,989 Reduced 6.97%	520,778 $10.9 Million
Q3 2024 Nov 14, 2024	BUY	$15.19 - $21.35 $6.53 Million - $9.18 Million	429,954 Added 331.21%	559,767 $11.1 Million
Q2 2024 Aug 14, 2024	BUY	$14.68 - $16.92 $371,066 - $427,686	25,277 Added 24.18%	129,813 $2.01 Million
Q1 2024 May 15, 2024	SELL	$13.18 - $17.11 $977,758 - $1.27 Million	-74,185 Reduced 41.51%	104,536 $1.67 Million
Q4 2023 Feb 14, 2024	SELL	$11.78 - $17.29 $1.61 Million - $2.36 Million	-136,340 Reduced 43.27%	178,721 $3 Million
Q2 2023 Aug 14, 2023	SELL	$11.5 - $18.08 $12 Million - $18.8 Million	-1,040,034 Reduced 76.75%	315,061 $4.23 Million
Q1 2023 May 15, 2023	SELL	$14.34 - $21.05 $13.7 Million - $20.2 Million	-958,571 Reduced 41.43%	1,355,095 $22.5 Million
Q4 2022 Feb 14, 2023	BUY	$12.25 - $19.5 $10.7 Million - $17 Million	873,308 Added 60.63%	2,313,666 $43 Million
Q3 2022 Nov 14, 2022	SELL	$7.06 - $15.52 $9.06 Million - $19.9 Million	-1,283,537 Reduced 47.12%	1,440,358 $18.5 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $8.57 $9.72 Million - $13.4 Million	1,560,086 Added 134.05%	2,723,895 $19.1 Million
Q1 2022 May 16, 2022	BUY	$5.31 - $8.31 $4.95 Million - $7.75 Million	932,377 Added 402.87%	1,163,809 $9.65 Million
Q4 2021 Feb 14, 2022	BUY	$5.21 - $7.45 $923,451 - $1.32 Million	177,246 Added 327.11%	231,432 $1.57 Million
Q3 2021 Nov 15, 2021	SELL	$4.85 - $6.04 $1.19 Million - $1.48 Million	-245,187 Reduced 81.9%	54,186 $287,000
Q2 2021 Aug 16, 2021	SELL	$4.29 - $6.05 $1.34 Million - $1.89 Million	-312,637 Reduced 51.08%	299,373 $1.72 Million
Q1 2021 May 17, 2021	BUY	$3.45 - $4.69 $603,487 - $820,393	174,924 Added 40.02%	612,010 $2.82 Million
Q4 2020 Feb 16, 2021	BUY	$2.97 - $3.83 $1.21 Million - $1.56 Million	406,817 Added 1344.01%	437,086 $1.46 Million
Q3 2020 Nov 16, 2020	SELL	$2.97 - $5.08 $697,308 - $1.19 Million	-234,784 Reduced 88.58%	30,269 $90,000
Q2 2020 Aug 14, 2020	SELL	$3.48 - $5.05 $1.98 Million - $2.87 Million	-567,948 Reduced 68.18%	265,053 $1.23 Million
Q1 2020 May 14, 2020	BUY	$2.61 - $5.21 $2.09 Million - $4.17 Million	801,306 Added 2528.18%	833,001 $3.21 Million
Q4 2019 Feb 14, 2020	SELL	$3.67 - $5.7 $162,034 - $251,660	-44,151 Reduced 58.21%	31,695 $119,000
Q3 2019 Nov 14, 2019	BUY	$3.89 - $7.43 $295,040 - $563,535	75,846 New	75,846 $402,000
Q4 2018 Feb 14, 2019	SELL	$1.92 - $3.62 $257,316 - $485,148	-134,019 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$2.81 - $3.78 $4.15 Million - $5.58 Million	-1,476,157 Reduced 91.68%	134,019 $507,000
Q2 2018 Aug 14, 2018	BUY	$2.26 - $3.84 $515,094 - $875,205	227,918 Added 16.49%	1,610,176 $5.02 Million
Q1 2018 May 15, 2018	SELL	$2.39 - $4.01 $1.64 Million - $2.75 Million	-684,622 Reduced 33.12%	1,382,258 $3.3 Million
Q4 2017 Feb 14, 2018	BUY	$2.51 - $4.4 $5.19 Million - $9.09 Million	2,066,880	2,066,880 $8.08 Million

Others Institutions Holding CPRX

# of Institutions

385

Shares Held

103M

Call Options Held

Put Options Held

277K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.09B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account